Literature DB >> 24347

Norepinephrine: hormone and neurotransmitter in man.

A B Silverberg, S D Shah, M W Haymond, P E Cryer.   

Abstract

To determine whether norepinephrine could subserve a hormonal as well as a neurotransmitter function, norepinephrine was infused for 60 min into each of five normal young men in doses of 0.1, 0.5, 1.0, 2.5, and 5.0 microgram/min. After infusion, the plasma norepinephrine concentration fell with a mean (+/-SD) half-time of 2.4 +/- 0.7 min. The mean (+/-SD) norepinephrine metabolic clearance rate was 3,070 +/- 200 ml/min. The calculated basal plasma norepinephrine production rate was 0.7 microgram/min. The blood pressure and circulating glycerol, acetoacetate, beta-hydroxybutyrate, and glucose (increased) and the heart rate and circulating insulin, lactate, pyruvate, and alanine (decreased) exhibited highly significant parabolic relationships with the steady-state plasma norepinephrine concentrations. However, norepinephrine levels in excess of 1,800 pg/ml were required to produce hemodynamic and/or metabolic effects. Thus, under usual conditions, the biologic actions of norepinephrine can be attributed only to its sympathetic neurotransmitter function. Plasma norepinephrine concentrations do at times exceed 1,800 pg/ml during exercise and during major acute illness. Thus, under conditions of stress, norepinephrine may subserve a hormonal, as well as a neurotransmitter, function.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 24347     DOI: 10.1152/ajpendo.1978.234.3.E252

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  50 in total

1.  Cold but not sympathomimetics activates human brown adipose tissue in vivo.

Authors:  Aaron M Cypess; Yih-Chieh Chen; Cathy Sze; Ke Wang; Jeffrey English; Onyee Chan; Ashley R Holman; Ilan Tal; Matthew R Palmer; Gerald M Kolodny; C Ronald Kahn
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

2.  Airway cooling and rewarming. The second reaction sequence in exercise-induced asthma.

Authors:  I A Gilbert; E R McFadden
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

3.  Determinants and importance of stress hyperglycaemia in non-diabetic patients with myocardial infarction.

Authors:  G A Oswald; C C Smith; D J Betteridge; J S Yudkin
Journal:  Br Med J (Clin Res Ed)       Date:  1986-10-11

Review 4.  Effects of catecholamines on secretion of adrenocorticotrophic hormone (ACTH) in man.

Authors:  S Al-Damluji; L H Rees
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

5.  Plasma catecholamine concentration during sedation in ventilated patients requiring intensive therapy.

Authors:  K L Kong; S M Willatts; C Prys-Roberts; J T Harvey; S Gorman
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

Review 6.  Pathophysiology of sympathoadrenal system.

Authors:  R Giorgino
Journal:  J Endocrinol Invest       Date:  1988-12       Impact factor: 4.256

Review 7.  Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

Authors:  P Pentel; N Benowitz
Journal:  Clin Pharmacokinet       Date:  1984 Jul-Aug       Impact factor: 6.447

8.  Defective glucose counterregulation after subcutaneous insulin in noninsulin-dependent diabetes mellitus. Paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production, roles of insulin resistance, abnormal neuroendocrine responses, and islet paracrine interactions.

Authors:  G B Bolli; E Tsalikian; M W Haymond; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Norepinephrine clearance and pressor effect in normal and hypertensive man.

Authors:  M Grimm; P Weidmann; G Keusch; A Meier; Z Glück
Journal:  Klin Wochenschr       Date:  1980-11-03

10.  Heart rate differences between right and left unilateral electroconvulsive therapy.

Authors:  C M Swartz; R Abrams; R D Lane; M A DuBois; J Srinivasaraghavan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-01       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.